Actively Recruiting

Phase 4
Age: 18Years - 70Years
FEMALE
NCT04136782

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Led by Shengjing Hospital · Updated on 2021-07-20

110

Participants Needed

7

Research Sites

280 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To investigate the efficacy of albumin-bound paclitaxel combined with carboplatin versus epirubicin combined with docetaxel as neoadjuvant therapy for triple-negative breast cancer.

CONDITIONS

Official Title

Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Who Can Participate

Age: 18Years - 70Years
FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Breast cancer confirmed by X-ray with tumor stage II-III and negative for estrogen receptor, progesterone receptor, and HER2
  • Estimated survival longer than 3 months
  • Presence of clinically measurable lesions
  • Karnofsky functional status score of 70 or higher
  • Normal blood tests, liver and kidney function, and near normal electrocardiogram
  • Age between 18 and 70 years
Not Eligible

You will not qualify if you...

  • Stage IV breast cancer with bone or other distant metastasis
  • Severe kidney failure
  • Serious heart or lung diseases making chemotherapy intolerable
  • Previous antineoplastic therapy
  • Failure of 2 cycles of neoadjuvant chemotherapy with change or termination of treatment
  • History of other cancers
  • Severe organ dysfunction or poor health unable to tolerate chemotherapy
  • Mental or nervous system disorders preventing treatment compliance
  • Allergy to dexamethasone or chemotherapy drugs
  • Pregnant or breastfeeding women
  • Participation in other clinical trials

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Cancer Hospital Affiliated to Harbin Medical University

Harbin, Heilongjiang, China, 150081

Actively Recruiting

2

The Second Hospital of Jilin University

Changchun, Jilin, China, 130041

Actively Recruiting

3

Dalian Municipal Central Hospital

Dalian, Liaoning, China, 116033

Actively Recruiting

4

Panjin Liaohe Oilfield Gem Flower Hospital

Panjin, Liaoning, China, 124010

Actively Recruiting

5

Shengjing Hospital of China Medical University

Shenyang, Liaoning, China, 110004

Actively Recruiting

6

The Fourth Affiliated Hospital of China Medical University

Shenyang, Liaoning, China, 110032

Actively Recruiting

7

Liaoning Cancer Hospital & Institute

Shenyang, Liaoning, China, 110042

Actively Recruiting

Loading map...

Research Team

X

Xi Gu, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here